Coherus BioSciences Inc (NAS:CHRS)
$ 1.785 0.025 (1.42%) Market Cap: 204.78 Mil Enterprise Value: 425.03 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Coherus BioSciences Inc at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 07:00PM GMT
Release Date Price: $19.89 (+14.35%)
Christopher Thomas Schott
JP Morgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott from JPMorgan and very happy to be introducing Coherus today. From Coherus, we have the company's President and CEO, Denny Lanfear.

With that, I'll turn it over to Denny.

Dennis M. Lanfear
Coherus BioSciences, Inc. - Chairman, President & CEO

Thank you, Chris. Let me first, of course, apprise you of the forward-looking statements and direct you to Coherus' various SEC filings, which address the various risks and so on with each of our products.

So today, I'm going to start talking about delivering on the promise of biosimilars. We founded this company, it'll be 10 years in September. And I think it's a good time, a year after launching UDENYCA, to take a step back and see how the biosimilar landscape has evolved. And I'm going to talk to you about the success of Coherus, particularly with UDENYCA, which we know, of course, was a breakthrough biosimilar product.

I'll go on and talk about our oncology

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot